Showing 1711-1720 of 5693 results for "".
- Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/Lytenava (Bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-reports-final-visit-for-last-patient-in-open-label-safety-study-for-ons-5010-lytenava-bevacizumab-vikg/2478861/Outlook Therapeutics announced that the last patient completed their final visit for the ongoing open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases (NORSE THREE). Two of the three planned clinical trials for the ONS-5010/Lytenava wet age
- Vertex Aims for “Virtual Clinic Visits” to Keep Ongoing Studies on Track Amid COVID-19 Pandemichttps://modernod.com/news/vertex-aims-for-virtual-clinic-visits-to-keep-ongoing-studies-on-track-amid-covid-19-pandemic/2477483/Vertex Pharmaceuticals said that due to the COVID-19 pandemic, the company is working with clinical trial sites to enable “virtual clinic visits” and home delivery of study drugs to ensure that ongoing trials continue as planned with the correct monitoring and procedures in place. How
- Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trialhttps://modernod.com/news/nicox-announces-last-patients-complete-final-visit-in-ncx-470-phase-3-mont-blanc-glaucoma-trial/2481100/Nicox announced that the last patients completed their final (3-month) visit in the Mont Blanc phase 3 clinical trial of NCX 470 0.1% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. A total of
- Santen Announces Initiation of Phase 3 Clinical Program (SPECTRUM) Evaluating Glaucoma Treatment Omidenepag Isopropyl (DE-117)https://modernod.com/news/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension/2479772/Santen announced the initiation of the pivotal phase 3 development program (SPECTRUM) in the United States, evaluating the investigational use of omidenepag isopropyl (DE-117), a selective agonist for the prostanoid receptor EP2, for the treatment of glaucoma or o
- Visual Clinic’s ‘Safe Visits’ Aims to Help Eye Care Clinics Comply with New Post-COVID-19 Protocolshttps://modernod.com/news/visual-clinics-safe-visits-aims-to-help-eye-care-clinics-comply-with-new-post-covid-19-protocols/2477921/Visual Clinic announced the launch of its Safe Visits application. The software module provides ophthalmology and optometry practices with a streamlined care process that safely and efficiently guides patients and staff through appointments in the post-COVID-19 environment, according to a company
- CMS Eases Requirements for COVID-19 Tests, Boosts Payments for Telephonic Visitshttps://modernod.com/news/cms-eases-requirements-for-covid-19-tests-boosts-payments-for-telephonic-visits/2477699/The Trump administration is easing requirements on testing for COVID-19 to make it easier to administer drive-thru and “parking lot” testing facilities, according to a FierceHealthcare
- Ora Names Gustavo De Moraes, MD, PHD, Chief Medical Officerhttps://modernod.com/news/ora-names-gustavo-de-moraes-md-phd-chief-medical-officer/2480622/Ora announced that distinguished op
- Conbercept Treatment of Wet AMD Completes 36-Week Primary Endpoint Visits of Phase 3 Trialhttps://modernod.com/news/conbercept-treatment-of-wet-amd-completes-36-week-primary-endpoint-visits-of-phase-3-trial/2478698/China-based Chengdu Kanghong Pharmaceutical Group announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, d
- Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trialhttps://modernod.com/news/last-patient-last-visit-completed-in-regenerx-phase-3-dry-eye-clinical-trial/2478508/RegeneRx Biopharmaceuticals announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up. ARISE-3 is designed to assess the safety and efficacy of 0.1% RGN-259 eye drops compared to placebo after 2 weeks of
- American Academy of Ophthalmology Urges Members to Immediately Stop Routine Surgical and In-Office Visitshttps://modernod.com/news/american-academy-of-ophthalmology-urges-members-to-immediately-stop-routine-surgical-and-in-office-visits/2477412/Due to the COVID-19 pandemic, the American Academy of Ophthalmology (AAO) stated that all ophthalmologists cease providing any treatment other than urgent or emergent care immediately. The statement posted on the AAO website reads: “We now live and practice in a critically di